Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Radiotheranostics using somatostatin receptor (R)-targeted agents has transformed the management of neuroendocrine tumors, yet its application in other oncological entities remains unexplored. Here, we report the firsSt-inST-human use of [Lu]Lu-DOTATATE in two patients with advanced, triple-class refractory multiple myeloma, selected based on dual imaging with [Ga]Ga-DOTATATE and [F]F-FDG PET/CT. Both patients received standard activities of [Lu]Lu-DOTATATE, resulting in favourable safety profiles and improved quality of life. One patient achieved sustained metabolic response and clinical stability over 12 months, while the second showed a complete metabolic response before experiencing biological progression. Treatment was associated with transient, non-clinically significant myelotoxicity. These findings support the feasibility of Peptide Receptor Radionuclide Therapy (PRRT) in multiple myeloma and suggest potential therapeutic benefit in selected patients. Further clinical investigation is warranted to validate these promising preliminary results.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12301282 | PMC |
| http://dx.doi.org/10.1186/s41824-025-00262-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Daratumumab-EPOCH for transformed anaplastic multiple myeloma.
Hematol Transfus Cell Ther
September 2025
Department of Haematology, Akershus University Hospital, Lørenskog, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway. Electronic address:
Discovery of Potential GPRC5D Inhibitors through Virtual Screening and Molecular Dynamics Simulations.
ChemistryOpen
September 2025
Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310003, China.
G protein-coupled receptor family C, group 5, member D (GPRC5D), a member of the G protein-coupled receptor (GPCR) family, has recently emerged as a promising target for immunotherapy in hematologic malignancies, particularly multiple myeloma. However, no systematic virtual screening studies have been conducted to identify small-molecule inhibitors targeting GPRC5D. To address this gap, a multistep computational screening strategy is developed that integrates Protein-Ligand Affinity prediction NETwork (PLANET), a GPU-accelerated version of AutoDock Vina (Vina-GPU), molecular mechanics/generalized born surface area (MM/GBSA), and an online tool for Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) property prediction (admetSAR 3.
View Article and Find Full Text PDFChronic kidney disease and incident cancer risk: an individual participant data meta-analysis.
Br J Cancer
September 2025
School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
Background: Studies examining the association of chronic kidney disease (CKD) with cancer risk have demonstrated conflicting results.
Methods: This was an individual participant data meta-analysis including 54 international cohorts contributing to the CKD Prognosis Consortium. Included cohorts had data on albuminuria [urine albumin-to-creatinine ratio (ACR)], estimated glomerular filtration rate (eGFR), overall and site-specific cancer incidence, and established risk factors for cancer.
Cancer and Post-Therapy Cardiotoxicity Risk in Adolescents, Young Adults, and Adults With Down Syndrome.
Compr Physiol
October 2025
Department of Internal Medicine, University of Iowa, Iowa City, IA, USA.
The median life expectancy of people with Down syndrome has increased substantially over the past several decades, from 4 years in 1970 to 53 years in 2010. Despite the recent improvement in survival, there is little data about the prevalence of age-related diseases, including age-related malignancies, and the impact of standard cancer treatments on cardiovascular health. We retrospectively reviewed medical records for age- and sex-matched patients ≥ 15 years old with and without Down syndrome using the TriNetX platform to identify the prevalence of malignancies and explore cardiovascular outcomes after treatment with anthracyclines.
View Article and Find Full Text PDFReal-World Comparison of Treatment Outcomes for Multiple Myeloma in Elderly Transplant Ineligible Patients Receiving First-Line VRd, Rd and VCd: Results From the Australian and New Zealand Myeloma and Related Diseases Registry.
Clin Lymphoma Myeloma Leuk
August 2025
Middlemore Hospital, Auckland, New Zealand.
Background: Real-world data on treatment outcomes for elderly transplant-ineligible patients with newly diagnosed multiple myeloma are limited. The difference in treatment subsidization in Australia compared with New Zealand enables comparison of bortezomib-cyclophosphamide-dexamethasone (VCd), lenalidomide-bortezomib-dexamethasone (VRd) with Rd maintenance, and continuous Rd.
Methods: Using data from the ANZ Myeloma and Related Diseases Registry, we evaluated 1092 patients over 70 years of age between February 2013 and February 2024.